WallStSmart

Merck & Company Inc (MRK)vsEntrada Therapeutics Inc (TRDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 1146083% more annual revenue ($65.77B vs $5.74M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

TRDA

Avoid

29

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 2/9Altman Z: 1.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued

Intrinsic value data unavailable for TRDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

TRDA2 strengths · Avg: 9.5/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.189/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TRDA4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$243.41M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : TRDA

The strongest argument for TRDA centers on Price/Book, Debt/Equity.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : TRDA

The primary concerns for TRDA are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

MRK carries more volatility with a beta of 0.20 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Entrada Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Entrada Therapeutics Inc. (TRDA) is a pioneering biotechnology firm focused on creating transformative therapies for severe diseases characterized by considerable unmet medical needs. Leveraging its proprietary Therapeutics for RNA Delivery (TRADA) platform, the company aims to tackle RNA and protein dysfunctions associated with various conditions, including muscular dystrophies and genetic disorders. With a robust clinical pipeline and a commitment to scientific excellence, Entrada is strategically positioned for impactful advancements in patient care. Backed by a seasoned management team, the company is set to make notable contributions to the biopharmaceutical landscape through its innovative therapeutic approaches.

Want to dig deeper into these stocks?